Brokers Set Expectations for Celldex Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Lifesci Capital issued their FY2024 earnings per share estimates for Celldex Therapeutics in a report released on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky forecasts that the biopharmaceutical company will post earnings of ($1.90) per share for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%.

Several other analysts also recently weighed in on the company. Guggenheim boosted their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Trading Down 0.4 %

Shares of Celldex Therapeutics stock opened at $41.06 on Thursday. The company has a fifty day simple moving average of $41.57 and a 200-day simple moving average of $37.05. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -14.11 and a beta of 1.60. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 5.9% during the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after purchasing an additional 300,406 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth $994,000. GSA Capital Partners LLP raised its stake in shares of Celldex Therapeutics by 192.0% during the 3rd quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company’s stock worth $1,231,000 after buying an additional 29,404 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Celldex Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock worth $9,950,000 after buying an additional 10,818 shares in the last quarter. Finally, Panoramic Investment Advisors LLC acquired a new stake in Celldex Therapeutics in the 4th quarter valued at about $258,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.